Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on APLS stock, giving a Buy rating yesterday. Tazeen Ahmad ...

Mizuho has reiterated its Neutral rating on Apellis Pharmaceuticals (NASDAQ: NASDAQ:APLS) with a steady price target of $42.00. The firm's stance comes ahead of the European Medicines Agency's ...

Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight-robbing condition that accompanies age-related macular degeneration (AMD ...

1 Day APLS -8.10% DJIA -0.14% S&P 500 -0.24% Health Care/Life Sciences 0.99% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...

After hours: September 20 at 7:59 PM EDT ...

After hours: 19 September at 19:59 GMT-4 ...

After hours: September 20 at 7:57 PM EDT Loading Chart for APLS ...